Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis

T. Buchler, Z. Bortlicek, A. Poprach, T. Pavlik, V. Veskrnova, M. Honzirkova, M. Zemanova, O. Fiala, K. Kubackova, O. Slaby, M. Svoboda, R. Vyzula, L. Dusek, B. Melichar, . ,

. 2016 ; 70 (3) : 469-75. [pub] 20151230

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18011309

Grant support
NV15-34678A MZ0 CEP Register

BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011309
003      
CZ-PrNML
005      
20201116155405.0
007      
ta
008      
180404s2016 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eururo.2015.12.031 $2 doi
035    __
$a (PubMed)26746623
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Buchler, Tomas $u Department of Oncology, Thomayer Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz.
245    10
$a Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis / $c T. Buchler, Z. Bortlicek, A. Poprach, T. Pavlik, V. Veskrnova, M. Honzirkova, M. Zemanova, O. Fiala, K. Kubackova, O. Slaby, M. Svoboda, R. Vyzula, L. Dusek, B. Melichar, . ,
520    9_
$a BACKGROUND: It is currently not known whether treatment with anti-vascular endothelial growth factor agents for metastatic renal cell carcinoma (mRCC) can be safely discontinued in patients achieving a complete response (CR). OBJECTIVE: To assess outcomes for patients with mRCC achieving CR on targeted therapy (TT) and the survival of patients discontinuing TT after CR. DESIGN, SETTING, AND PARTICIPANTS: A national registry was used to identify patients achieving CR during first-line TT using bevacizumab, sunitinib, sorafenib, or pazopanib. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcomes were analysed using a log-rank test. RESULTS AND LIMITATIONS: A total of 100 patients achieving CR were identified out of 2803 patients. The median time to CR was 10.1 mo. Median progression-free survival (PFS) from TT initiation was 3.8 yr (95% confidence interval [CI] 2.9-4.6 yr) and the 5-yr overall survival (OS) was 80% (95% CI 70-91%). Patients discontinuing TT within 1 mo after achieving CR and those continuing TT beyond CR had similar OS (CI for difference in 2-yr post-CR OS -13% to 19%; p=0.3) and PFS (CI for difference in 2-yr post-CR PFS -29% to 17%; p=0.7). The limitations include the retrospective, registry-based data analysis. CONCLUSIONS: Achievement of CR on TT for mRCC was associated with excellent long-term prognosis. No significant differences in post-CR survival were observed between patients discontinuing TT after the date of CR and those who continued on TT, although the wide CIs cannot exclude important differences between the groups. PATIENT SUMMARY: According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.
650    _2
$a senioři $7 D000368
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a bevacizumab $x terapeutické užití $7 D000068258
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x sekundární $7 D002292
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a nádory ledvin $x farmakoterapie $x patologie $7 D007680
650    _2
$a nádory plic $x farmakoterapie $x sekundární $7 D008175
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a niacinamid $x analogy a deriváty $x terapeutické užití $7 D009536
650    _2
$a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x antagonisté a inhibitory $7 D040262
650    _2
$a registrace $7 D012042
650    _2
$a kritéria léčebné odpovědi $7 D066066
650    _2
$a sulfonamidy $x terapeutické užití $7 D013449
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nenasazení léčby $7 D028761
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Pavlik, Tomas $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Veskrnova, Veronika $u Department of Oncology, Thomayer Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Honzirkova, Michaela $u Department of Oncology, Thomayer Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology, University Hospital, Pilsen, Czech Republic.
700    1_
$a Kubackova, Katerina $u Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a ,
773    0_
$w MED00001669 $t European urology $x 1873-7560 $g Roč. 70, č. 3 (2016), s. 469-75
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26746623 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20201116155403 $b ABA008
999    __
$a ok $b bmc $g 1288794 $s 1008121
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 70 $c 3 $d 469-75 $e 20151230 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20180404
Back

Find record

Citation metrics

Archiving options